, Norbert Ifrah Provision of study materials or patients Jean-Jacques Sotto Collection and assembly of data Lioure Data analysis and interpretation, Norbert Ifrah Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors REFERENCES
, Treatment of acute myeloid leukemia: Are we making progress?, Hematology Am Soc Hematol Educ Program, vol.2012, pp.1-6, 2012.
, Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia, New England Journal of Medicine, vol.331, issue.14, pp.896-9031051, 1994.
DOI : 10.1056/NEJM199410063311402
, Age and acute myeloid leukemia, Blood, vol.107, issue.9, pp.3481-34851894, 2006.
DOI : 10.1182/blood-2005-09-3724
, Treatment of acute myelogenous leukemia in older adults, Leukemia, vol.14, issue.3, pp.480-487, 2000.
DOI : 10.1038/sj.leu.2401539
, Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia, Hematology/Oncology Clinics of North America, vol.25, issue.6
DOI : 10.1016/j.hoc.2011.09.018
, Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study, Hematol Oncol Clin North Am Blood, vol.25, issue.89, pp.1135-11613323, 1997.
, Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Survival for older patients with acute myeloid leukemia: A populationbased study Management of older or unfit patients with acute myeloid leukemia A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia Androstane therapy to treat aplastic anaemia in adults: An uncontrolled pilot study, 14. Najean Y, Haguenauer O: Long-term (5 to 20 years) evolution of nongrafted aplastic anemias, pp.4179-4187770, 1916.
, Further observations in 24 cases A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: A pilot study Treatment of acute myeloid leukemia in elderly patients: The influence of maintenance therapy (BGM 84 protocol), Neckers LM: Sensitive and simple bioassay for human tumour necrosis factoralpha, pp.953-967617, 1980.
, Effects of two sex steroids (17beta estradiol and testosterone ) on proliferation and clonal growth of the human monoblastic leukemia cell line, U937 Effects of homo-aza-steroids on acute non-lymphocytic leukaemia cell proliferation in vitro An international system for human cytogenetic nomenclature Report of the Standing Committee on Human Cytogenetic Nomenclature Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results, Leuk Res Leuk Res Br J Haematol Birth Defects Orig Artic Ser Haematologica, vol.23, issue.92, pp.369-372, 1978.
, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group Mitoxantrone versus daunorubicin in inductionconsolidation chemotherapy: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation, Haferlach T, Kohlmann A, Wieczorek L, et al: Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group, pp.4496-4504, 2010.
, Saint Etienne All rights reserved, Androgens as Maintenance Therapy in Elderly Patients With AML Downloaded from ascopubs.org by Institut National de la Sant et de la Recherche Mdicale on, 2017.
, Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy
, Chugai Pharmaceutical, Celgene Philippe Guardiola No relationship to disclose Christian Recher Consulting or Advisory Role: Celgene, Sunesis Pharmaceuticals, Novartis, Amgen Research Funding: Amgen, Novartis, Chugai Pharmaceutical, Celgene Jean-Francois Hamel No relationship to disclose Mathieu Sauvezie No relationship to disclose Jean-Luc Harousseau No relationship to disclose Olivier Tournilhac Honoraria, Amgen (Inst) Travel
, Nathalie Fegueux No relationship to disclose Chantal Himberlin No relationship to disclose Mathilde Hunault No relationship to disclose Martine Delain No relationship to disclose Bruno Lioure No relationship to disclose Eric Jourdan Honoraria: Novartis, Cell Therapeutics, Sanofi Frederic Bauduer No relationship to disclose Francois Dreyfus No relationship to disclose Jean-Yves Cahn Consulting or Advisory Role: Celgene, Alexion Pharmaceuticals, Novartis, Sunesis Pharmaceuticals Research Funding: Novartis, Chugai Pharma Travel, Accommodations, Expenses: Amgen, Alexion Pharmaceuticals, Janssen-Cilag Jean-Jacques Sotto No relationship to disclose Norbert Ifrah Honoraria: Celgene, Celgene (Inst) Travel
, Centre Hospitalier; B. Desablens, Amiens, Centre Hospitalo-Universitaire-H ? opital Sud
, Centre Hospitalo-Universitaire Hautepierre; F. Huguet-Rigal We thank the local and central data managers for collecting patient data